Sabin Vaccine Institute Partners with King Saud University to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.

Last year, the leaders of some of the wealthiest nations pledged help control and eliminate the most common neglected tropical diseases (NTDs) by 2020.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

This article was originally posted on the DSW Blog.

Photo: Sabin CEO Michael W. Marine, Ambassador (Ret.), with Former President of Ghana, John Kufuor

I am so thrilled to be here with y’all at the Global Network for Neglected Tropical Diseases’ Second Annual END7 Student Advocacy Day. I’m Barbara Bush and I’m the CEO & co-Founder of Global Health Corps.
Sabin’s President, Dr. Peter Hotez, received the 2015 RESULTS Seeds of Hope Award on Sunday in Houston, Texas. Each year, this award honors a person in the Houston community who has made extraordinary contributions towards improving health, education or microfinance — the three pillars of RESULTS advocacy. This year’s award honored advances in Child and Maternal Health.
Global Communities had spent four years building access to safe sanitation in Liberia when the Ebola epidemic struck and revealed a surprising impact.

Pages